Nucleophosmin (NPM, also known as B23, numatrin or NO38) is a ubiquitously expressed phosphoprotein belonging to the nucleoplasmin family of chaperones. NPM is mainly localized in the nucleolus where it exerts many of its functions, but a proportion of the protein continuously shuttles between the nucleus and the cytoplasm. A growing number of cellular proteins have been described as physical interactors of NPM, and consequently, NPM is thought to have a relevant role in diverse cellular functions, including ribosome biogenesis, centrosome duplication, DNA repair and response to stress. NPM has been implicated in the pathogenesis of several human malignancies and intriguingly, it has been described both as an activating oncogene and a tumor suppressor, depending on cell type and protein levels. In fact, increased NPM expression is associated with different types of solid tumors whereas an impairment of NPM function is characteristic of a subgroup of hematolologic malignancies. A large body of experimental evidence links the deregulation of specific NPM functions to cellular transformation, yet the molecular mechanisms through which NPM contributes to tumorigenesis remain elusive. In this review, we have summarized current knowledge concerning NPM functions, and attempted to interpret its multifaceted and sometimes apparently contradictory activities in the context of both normal cellular homeostasis and neoplastic transformation. Oncogene (2011 Oncogene ( ) 30, 2595 Oncogene ( -2609 doi:10.1038 /onc.2010 ; published online 31 January 2011
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Nucleophosmin (NPM) is a multi-functional cellular chaperone
NPM is the product of the NPM1 gene, which in humans contains 12 exons and maps to chromosome 5q35; two isoforms of the NPM protein, derived from alternative splicing of the NPM1 transcript, have been reported (Wang et al., 1993) (Figure 1 ). In the long isoform, known as B23.1, exon 9 is spliced to exon 11 and the coding sequence stops at exon 12, resulting in a protein of 294 residues. In the short isoform, B23.2, exon 9 is spliced to exon 10 that immediately contains a stop codon, and as a result, B23.2 is a truncated protein of 259 residues. The prevalent form expressed in all tissues is B23.1, although the biological significance and physiological function of B23.2 remain largely unclear. In the human EST database a further transcript variant that lacks exon 8 has been identified (GenBank accession number: NM_199185). Its functional role as well as its tissue distribution are currently totally unknown.
NPM is biochemically defined as a histone chaperone (Frehlick et al., 2007) . It belongs to the nucleoplasmin/ nucleophosmin family of nuclear chaperones, sharing the core-domain at the N-terminus of the protein. This portion of the NPM protein includes an acidic tract and is responsible for oligomerization and chaperone activity (Hingorani et al., 2000) . Histone chaperones are required for the correct assembly/disassembly of nucleosomes, and therefore are necessary for DNA-dependent activities like transcription, replication and repair (Eitoku et al., 2008) . Accordingly, NPM has been isolated as a putative histone chaperone using a series of in vitro assays that reveal chromatin related functions. Okuwaki et al., (2001a) showed that NPM favors replication of adenovirus DNA in complex with viral basic core proteins (viral nucleosome). They also demonstrated that NPM interacts with human histones, binds preferentially to histone (H3-H4) 2 tetramers and is able to transfer nucleosomes to naked DNA favoring chromatin assembly. On the other hand, NPM, like other histone chaperones, decondenses sperm chromatin (Okuwaki et al., 2001b) . Therefore, NPM behaves in vitro as a classical histone chaperone favoring assembly and disassembly of chromatin templates. Whether this is a major role of NPM also in vivo is less clear. NPM is part of the centromere protein A protein complex, which represents the nucleosome variant that replaces H3 in centromeric nucleosomes. (Foltz et al., 2006 (Foltz et al., , 2009 However, if NPM is required for centromere-specic assembly of centromere protein A nucleosomes has not been fully investigated.
A number of reports implicate NPM in the control of DNA transcription, in most cases through the interaction with a variety of different transcription factors. NPM can either contribute to transcriptional activation, as in the case of Myc-interacting zinc finger protein 1 (Miz1) (Wanzel et al., 2008) , androgen receptor (Leotoing et al., 2008) , ribosomal genes (Murano et al., 2008) , c-Myc (Li et al., 2008) and nuclear factor of k light polypeptide gene enhancer in Bcells (NF-kB) (Dhar et al., 2004) , or to repression, as for the activating protein transcription factor 2 (AP2a) (Liu et al., 2007a) . However, the exact mechanism through which NPM mediates these regulatory activities is not completely elucidated, and it is unclear if it functions as a general co-factor during transcription or if it is physically associated to specific promoters. In support of a more general role for NPM in transcriptional regulation, it has been reported that NPM interacts with and inhibits the activity of hexamethylene bis-acetamide inducible 1 (HEXIM1), a negative regulator of Pol IIdependent transcription (Gurumurthy et al., 2008) . Furthermore, NPM has been involved in different ways and at different levels as a modulator of chromatin status. In fact, NPM was found to enhance acetylationdependent transcription of an artificial chromatin template, likely by removing acetylated histones (Swaminathan et al., 2005) . In a different experimental setting, Zou and colleagues recently showed that NPM blocks chromatin acetylation mediated by the activity of lysine acetyltransferase 2A (GCN5), and inhibits GCN5 dependent transactivation in a cell-based assay. Intriguingly, NPM has been found associated with the CCCTC-binding factor, an insulator binding protein implicated in higher order chromatin organization (Yusufzai et al., 2004; Liu et al., 2008) .
Beside its specific role as histone chaperone, NPM displays a broad chaperone activity both in vitro and in vivo. In vitro functional studies suggest that NPM displays chaperone-like behaviors on a wide variety of denatured substrates: (i) NPM inhibits temperaturedependent and independent protein aggregation, due to thermal denaturation, protecting enzymes from loss of activity; (ii) NPM promotes renaturation of chemically denatured proteins and it appears to preferentially bind denatured substrates through the exposure of hydrophobic regions in both NPM and substrates (Szebeni and Olson, 1999) . Although NPM binds ATP, at least in vitro (Chang et al., 1998) , its binding to substrates is governed by association-dissociation thermodynamics, and release of the substrate does not require ATP hydrolysis (Szebeni and Olson, 1999) , as seen with other molecular chaperones including Hsp70 and chaperonins (Ruddon and Bedows, 1997) . Interestingly, it has been shown that phosphorylation of NPM by casein kinase II induces the release of denaturated substrates (Szebeni et al., 2003) . In the case of specific interactions between NPM and its binding partners, which involve defined protein domains, such as the human immunodeficiency virus-Rev protein, NPM phosphorylation does not affect the interaction (Szebeni et al., 2003) . All these data come from in vitro studies using recombinant proteins, therefore, we do not know if NPM shows the same behavior in living cells. However, there are a number of reports showing that NPM is required in cells for the correct localization and/or stability and activity of some of its interactors.
NPM modulates the half-life and the nucleolar localization of many of its most relevant binding partners, including the tumor suppressors ARF (p19 ARF in mouse, p14 ARF in human) (Kuo et al., 2004; Colombo et al., 2005) , F-box and WD repeat domain containing 7 (Fbw7g) (Bonetti et al., 2008) Figure 1 Schematic representation of NPM isoforms and AML-associated NPM mutant. Relevant functional domains are highlighted together with the aminoacidic position in parentheses. Modified aminoacids (phosphorylated and sumoylated) are also indicated. S4: serine4, phosphorylated by polo-like kinase 1 (Plk1) in mitosis and by Plk2 in S-phase. S10: serine10, phosphorylated by unknown CDK, involved in G2-M transition. S70: serine70, phosphorylated by unknown CDK, involved in G2-M transition. S125: serine125, phosphorylated by casein kinase II and ATR; involved in DNA damage response, chaperone activity and NPM1 mobility. T199: threonine199, phosphorylated by CDK2 in G1 and CDK1 in mitosis; involved in centrosome duplication and DNA damage response. T219: threonine219, phopshorylated by CDK1 in mitosis; involved in RNA binding. R230: arginine230, sumoylated; involved in stability, localization, proteins interaction, apoptosis. T234/37: threonine234/37, phosphorylated by CDK1 in mitosis; involved in RNA binding. S254: serine 254, phosphorylated by unknown kinase in mitosis. R263: arginine263, sumoylated; involved in stability, localization, proteins interaction and apoptosis.
Nucleophosmin and its complex network E Colombo et al SUMO1/sentrin/SMT3 specific peptidases 3 and 5 (SENP3-5) (Yun et al., 2008) , and influences the stability of the cell cycle inhibitor p21/WAF/CIP (p21) (Xiao et al., 2009) . Moreover, the chaperone activity of NPM has been linked to its ability to assist the transport of other proteins across the nuclear membrane. Indeed, NPM itself is a protein that shuttles between nucleus and cytoplasm (Borer et al., 1989) and, accordingly, it contains both a nuclear localization signal and a nuclear export signal Yu et al., 2006) . In vitro, NPM facilitates the nuclear import of other nuclear localization signal containing proteins (Szebeni et al., 1997) . On the other hand, NPM is required for ribosomal protein L5 nuclear export (Yu et al., 2006) and, more in general, for the export of pre-ribosomal nuclear particles (Maggi et al., 2008) . The correlation between NPM and ribosome biogenesis is even more complex. The NPM long isoform B23.1 is manly localized in the granular region of the nucleolus (while the B23.2 isoform is prevalently nuclear diffuse) (Wang et al., 1993) , and this specific localization correlates with its reported activity in the stimulation of ribosomal DNA transcription (Murano et al., 2008) and processing of ribosomal RNA precursors (prerRNA) (Savkur and Olson, 1998) . More recently, it was shown that NPM binds the second internal transcribed spacer (ITS2) of the pre-rRNA leading to the release of 28S ribosomal RNA. Accordingly, it has been reported that inhibition of NPM expression leads to a decrease in 28S rRNA levels, and accumulation of the 32S intermediate (Itahana et al., 2003) .
However, the RNA binding activity of NPM does not seem to be confined to ribosomal RNA (Herrera et al., 1995) . In fact, it has been shown that NPM is selectively deposited on mRNA during polyadenylation, but the biological significance of this binding remains unknown (Palaniswamy et al., 2006) . More recently, NPM has been reported to bind the 3 0 untranslated region of the product of the chicken connective tissue growth factor gene, ccn2, triggering its degradation, and this mechanism contributes to modulate chondrocyte differentiation (Mukudai et al., 2008) .
NPM controls cell cycle progression and cell survival NPM is generally reported as a protein that promotes cellular growth and survival upon apoptotic stimuli and it appears to regulate these functions in a cell-type specific manner. Furthermore, in hematopoietic cells, NPM expression decreases during differentiation and NPM overexpression limits maturation rate both in vitro (Hsu and Yung, 2000; Chou et al., 2007) and in vivo . Intriguingly, in hematopoietic stem cells NPM overexpression also increases self-renewal, repopulating ability and survival to DNA damage . In a neuronal cell line (PC12) NPM was shown to be required for nerve growth factor-dependent antiapoptotic activity by inhibiting the DNA fragmentation capacity of the caspase-activated DNase (Ahn et al., 2005) . Another pathway through which NPM exerts an anti-apoptotic response involves the interferon inducible double-stranded RNA-dependent protein kinase PKR. NPM binds PKR and inhibits its pro-apoptotic activities both in mouse embryo fibroblasts (MEFs) and in Fanconi-anemia derived lymphoblasts (Pang et al., 2003) . Dhar and St Clair (2009) , recently showed that, although NPM overexpression favors stabilization of the tumor suppressor p53 and, consequently, results in increased levels of its targets p21 and BCL2-associated X protein (BAX), it simultaneously prevents the proapoptotic accumulation of p53 in the mitochondria, thus limiting the apoptotic response (Dhar and St Clair, 2009 ). On the other hand, it has been reported that, in neuronal cells, NPM, following apoptotic stimuli (such as staurosporine in vitro and ischemia in vivo), translocates from the nucleolus to the cytoplasm where it binds to BAX and p53 favoring mitochondrial cytochrome-c release and apoptosis (Kerr et al., 2007) . These data suggest that NPM, as nuclear-cytoplasmic molecular chaperone, may change cell fate depending on the stimulus, cell type and activated pathway.
A number of reports have demonstrated that overexpression of NPM in different cellular contexts correlates with increased cellular survival upon stress. In fact, NPM overexpressing cells were more resistant to ultraviolet irradiation (Wu et al., 2002a, b; Maiguel et al., 2004) , ionizing radiation (Dalenc et al., 2002) , hypoxia (Li et al., 2004) , oncogenic overexpression (Li et al., 2007) and actinomycin D treatment (Yao et al., 2010) . A possible explanation lies in the observation that overexpression of NPM has been associated to reduced levels of damaged DNA in cells (Li et al., , 2007 or to increased DNA repair activity (Wu et al., 2002a, b) . Although the molecular mechanisms are largely unknown, it has been shown that in response to hypoxia (Li et al., 2004) and UV (Maiguel et al., 2004) , NPM limits the phosphorylation of p53 on serine 15, a posttranslational modification that stabilizes p53 and thus favors the p53-dependent apoptotic response (Appella and Anderson, 2001 ). These data have been interpreted as NPM being a negative regulator of p53 stabilization, therefore limiting apoptosis; however, based on available data, one can envision an alternative scenario in which NPM, by limiting the extent of DNA damage (either directly preventing damage and/or favoring DNA repair), can attenuate the DNA-damage response (DDR) and, consequently, diminish the levels of DDRdependent p53 phosphorylation and inhibiting apoptosis. In support of this view, NPM was shown to suppress oncogene-induced apoptosis through mechanisms that involve diminished levels of DNA damage. In fact, MEFs that are either wild type (WT) or defective for DNA repair pathways but overexpressing NPM showed increased survival upon overexpression of c-Myc, which correlated with a decrease of c-Myc induced DNA damage and, therefore, attenuated p53 stabilization (Li et al., 2007) .
On the other hand, it has been shown that NPM directly interacts with p53 and its overexpression in primary diploid fibroblast leads to p53 stabilization and senescence. Downregulation of NPM reduces p53 stabilization in response to different stress stimuli and therefore reduces p53-dependent cell cycle arrest (Colombo et al., 2002) . The effect of NPM on the cell cycle may partly be due to its reported role in controlling the nuclear translocation of growth arrest and DNA-damage-inducible a-protein (GADD45a), a target of p53 and of the tumor suppressor BRCA1 that is required for G2-M cell cycle arrest, apoptotic response and DNA repair (Gao et al., 2005) . Along the same line, Kurki et al. showed that in response to UV, NPM undergoes nucleoplasmic redistribution and binds to HDM2 (Mdm2 in mouse). HDM2 functions as an E3 ligase that ubiquitinates p53 contributing to its rapid turnover in cycling cells. Binding of NPM to HDM2 prevents its interaction with p53 and leads to p53 stabilization (Kurki et al., 2004 ).
It appears, therefore, that upon UV treatment, NPM has the same function described for ARF in response to oncogenic stimuli (Weber et al., 1999) . ARF is a nucleolar protein that triggers oncogene-induced cell cycle arrest mainly through the inhibition of Mdm2-mediated p53 degradation. It was originally proposed that ARF sequesters Mdm2 in the nucleolus where it can not bind and ubiquitinate p53 (Weber et al., 1999) . More recently, other reports showed that p53 is also stabilized in the absence of nucleolar Mdm2 and that non-nucleolar forms of ARF can also activate p53 and suppress growth, thus suggesting that nucleolar localization is not required for ARF activity (Llanos et al., 2001; Korgaonkar et al., 2002) . Moreover, it has become clear that ARF can induce cell cycle arrest in the absence of p53 (Weber et al., 2000) , and this activity has been related to the ability of ARF to inhibit ribosomal RNA processing (Sugimoto et al., 2003) . NPM has been reported as the main interactor of ARF in the cell (Itahana et al., 2003; Bertwistle et al., 2004) . ARF mutants that do not bind NPM are highly unstable, get rapidly degraded by the proteasome and display very low anti-proliferative activity (Kuo et al., 2004) . These data, together with the highly unstable structure of ARF (Bothner et al., 2001) , strongly suggest that NPM is the molecular chaperone that favors the correct folding of ARF in cells. Accordingly, NPMÀ/À cells express very low levels of ARF, which is rapidly degraded, and fails to localize in the nucleolus (Colombo et al., 2005) . Indeed, only the nucleolar pool of ARF is stable (Rodway et al., 2004) . In summary, NPM binds ARF and is required for its correct nucleolar localization and stability in the cell.
The biological consequences of the NPM-ARF interaction are a matter of debate. It has been reported that downregulation of NPM leads to ARF relocation to the nucleoplasm and p53 stabilization, thus suggesting that NPM sequesters ARF in the nucleolus preventing its binding to Mdm2 (Korgaonkar et al., 2005) . However, NPM downregulation leads to p53 activation and cell cycle arrest even in the absence of ARF, due to accumulation of DNA damage in the cells (Colombo et al., 2005) . Therefore, it is generally difficult to investigate p53-dependent ARF pathways in the absence of NPM due to overlapping but independent cellular events. Itahana et al. (2003) reported that ARF negatively regulates NPM stability in a sort of feed-back loop, leading to decreased pre-rRNA processing, thus suggesting that NPM is the main target of ARF in its ability to inhibit ribosomal RNA processing. On the other hand, Brady et al. (2004) did not confirm either ARF-dependent NPM degradation and/or ARFdependent inhibition of pre-rRNA processing, but showed that ARF blocks NPM shuttling, likely interfering with ribosome biogenesis, and that NPM competes with Mdm2 for ARF binding thus favoring p53 degradation. It must be noted that all these reported ARF activities on NPM stability and shuttling require high levels of exogenous ARF overexpression in the cells; however, in endogenous conditions, their stoichiometry is quite different and, although most of ARF is bound to NPM, a large proportion of endogenous NPM protein is not bound to ARF . Therefore, it is still not clear if these reported and contradictory mechanisms may have a role in physiological conditions.
It has been shown that MEFs lacking both NPM and p53 have an increased proliferative rate compared with MEFs lacking only p53. ARF expression is induced by oncogenic stimuli both in vitro (Lowe and Sherr, 2003) and in vivo (Ventura et al., 2007) . In the double knockout cells, ARF levels are lower, thus suggesting that in these cells ARF no longer contributes to the control of cell cycle progression. Accordingly, ectopic expression of oncogenes in MEFs lacking both p53 and NPM failed to induce high levels of ARF expression leading to increased oncogene-dependent cellular growth and transformation (Colombo et al., 2005) .
In conclusion, beside the difficulties in establishing a unified model, available data clearly indicate that the NPM-ARF interaction has a central role in controlling their cellular functions. Further studies are required to establish their relative contribution in cancer development.
Regulation of NPM activities through post-translational modifications
Different post-translational modifications have been reported for NPM, which correlate with a specific activity and/or subcellular localization (Figure 1 ).
Phosphorylation NPM was originally defined as a phosphoprotein and, indeed, many kinases have been shown to phosphorylate NPM. As it will become clear, phosphorylation of NPM at different sites seems to be important in regulating cell cycle progression at multiple steps. Threonine 199 (T199) is phosphorylated by the Cdk2-cyclinE complex during G1-S transition and this phosphorylation event is required for centrosome duplication (Okuda et al., 2000) . In fact, cells expressing a T199A NPM mutant display defects in centrosome number leading to abnormal mitosis (Tokuyama et al., 2001) . Interestingly, in p53À/À MEFs, which display an abnormal number of centrosomes, either the absence of CDK2/CDK4 activity or the presence of a T199A NPM mutant is sufficient to revert this phenotype (Adon et al., 2009) . A functional nuclear export signal and the capacity to bind to the Ran-Crm1 nuclear export signal-dependent nuclear export complex, are required to localize NPM to centrosomes and control their duplication . T199 phosphorylation has been also linked to specific NPM localization in nuclear speckles where it represses pre-mRNA processing (Tarapore et al., 2006) and, more recently, T199 phosphorylated NPM has been shown to accumulate at sites of DNA damage favoring DNA repair (Koike et al., 2010) . T199 together with T219, T234 and T237 are phosphorylated before mitosis by the Cdk1-cyclinB complex, abolishing the RNA binding activity of NPM (Peter et al., 1990; Okuwaki et al., 2002) .
The exact role of NPM in mitosis is not known but lack of phosphorylation or lack of NPM expression has been reported to result in spindle check-point activation due to severe mitotic defects such as improper mitotic spindle formation and defects in kinetokore-microtubule attachment Amin et al., 2008) . During mitosis, NPM is mainly dispersed throughout the cell with a minor fraction located at the spindle poles and its phosphorylation is required for this localization (Yao et al., 2004; Negi and Olson, 2006) . Several sites are phosphorylated in mitosis: S4 by polo-like kinase 1 (but also in S-phase by Plk2 (Krause and Hoffmann, 2010) ), and S70 and S254 by unknown kinases (Nousiainen et al., 2006) . Moreover, NPM is a target of the NimA-like protein kinase (Nek2A), although the phosphorylation sites have not been mapped (Yao et al., 2004) . Recently, it has been shown that the NPM S10A-S70A phospho-mutant blocks cellular proliferation at G2-M, whereas the phosphomimetic NPM mutant (S10E/S70E) overrides stressinduced G2-M arrest favoring the interaction between CDK1 and Cdc25c through Cdc25c nuclear retention (Du et al., 2009) , further strengthening the relevance of NPM phosphorylation in the control of mitosis.
Another relevant NPM phosphorylation site is serine 125. This site is a target of casein kinase II and is required for the release of NPM substrates during in vitro chaperone tests (Szebeni et al., 2003) . Interestingly, S125-phosho NPM is more mobile, although the biological consequences have not been investigated (Negi and Olson, 2006) ; more recently, casein kinase II dependent NPM phosphorylation has been linked to NPM nuclear retention and matrix association . Serine 125 has also been reported to be phosphorylated by ataxia telangiectasia and Rad3 related kinase (ATR) in response to UV irradiation by Maiguel et al. The authors suggest that NPM phosphorylation by ATR competes with p53ser15 phosphorylation, as NPM overexpression leads to a decrease in p53ser15 phosphorylation upon UV (Maiguel et al., 2004) . This result, however, also may be ascribed to decreased levels of damaged DNA and/or increased DNA repair activity in cells overexpressing NPM, as previously discussed. Acetylation Shandilya et al. recently reported that NPM is acetylated by the p300 acetyltransferase enzyme and de-acetylated by the NAD-dependent deacetylase sirtuin-1 (SIRT1) both in vitro and in living cells. Acetylated NPM co-localizes in the nucleoplasm with RNA PolII, likely inducing its transcriptional activity. Interestingly, acetylated NPM is increased in oral carcinomas and is enriched on the promoter of genes implicated in tumor progression (Shandilya et al., 2009 ).
Sumoylation
Two sumoylated lysines have been mapped in the NPM protein: K230 and K263, the latter representing the main sumoylation site (Liu et al., 2007b) . The K263R NPM mutant does not correctly localize to the nucleolus or at centrosome, leading to altered regulation of centrosomal duplication and likely interfering with NPM dependent cell cycle regulation (Liu et al., 2007b) . However, Haindl et al. found that the NPM K263R mutant is still sumoylated and does not alter its nucleolar localization. They alternatively propose that sumoylation of NPM prevents its activity in regulating pre-rRNA processing (Haindl et al., 2008) . Moreover, NPM sumoylation has been reported to control the binding of NPM to the tumor suppressor retinoblastoma protein (pRb), leading to pRb nucleolar sequestration and activation of the transcription factor E2F1 (Liu et al., 2007b) , thus contributing to cell cycle control. NPM is also associated with the two isoforms of the ErbB-3 binding protein 1, a RNA binding protein involved in the control of cell proliferation and apoptosis. In particular, the p42 isoform of ErbB-3 binding protein 1 binds only to unsumoylated NPM in response to growth factors, whereas the p48 isoform constitutively binds sumoylated NPM. Impairment of the association between NPM and ErbB-3 binding protein 1 isoforms leads to decreased cell proliferation and increased apoptosis (Okada et al., 2007) .
The sumoylation status of NPM may also have a role in controlling its stability. Sumoylation protects NPM from proteolytic cleavage upon staurosporine-induced apoptosis, (Liu et al., 2007b) both in HeLa and PC12 cells. However, following growth factor stimulation, as in PC12 cells treated with nerve growth factor, unsumoylated NPM strongly interacts with the protein kinase Akt in the nucleoplasm and this interaction protects NPM from proteolytic cleavage and increases cell survival . Therefore, sumoylation may have different effects on NPM stability that depend on protein localization and cellular state.
NPM is sumoylated upon ARF overexpression through an indirect mechanism that involves SENP3, a nucleolar SUMO2-3 deconjugating protease (Tago et al., 2005) . ARF induces the phosphorylation, ubiquitination and degradation of SENP3, which desumoylates NPM among other substrates (Nishida and Yamada, 2008) . Therefore, ARF and SENP3 compete to control the level of NPM sumoylation (Haindl et al., 2008; Kuo et al., 2008) . However, ARF requires NPM to induce SENP3 degradation and, on the other hand, NPM is required for the correct nucleolar localization and stability of both ARF and SENP3 (Kuo et al., 2008; Yun et al., 2008) . ARF and SENP3 do not seem to compete for NPM binding suggesting that NPM may provide a molecular platform in which ARF and SENP3 can meet and counteract each other's activities. Although SENP3 downregulation prevents pre-rRNA processing similarly to what is observed upon NPM downregulation (Haindl et al., 2008) , it is unlikely that NPM is the main target of the ARF-SENP3 pathway in controlling the cell cycle. In fact, in cells lacking NPM the level of SUMO2/3 modified proteins (other than NPM) is increased in the nucleolus, and downregulation of SENP3 causes cell cycle arrest in NPM null cells as well as in cells expressing NPM (Kuo et al., 2008) .
Ubiquitination NPM is a very stable protein and little is known about the proteasome-dependent regulation of its turnover. However, NPM is a target of ubiquitination and this modification may modulate different NPM functions. NPM is targeted by the BRCA1/BARD1 ubiquitin ligase complex, which catalyzes an unusual Lys-6-linked polyubiquitin chain that does not induce proteasomedependent degradation but, on the contrary, stabilizes NPM (Sato et al., 2004) . NPM and the BRCA1/BARD1 complex co-localize in mitosis and the ubiquitin-ligase activity of BRCA1/BARD1 is required in mitosis for a correct mitotic spindle assembly, in accordance with the reported role of BRCA1 in maintaining chromosome stability (Joukov et al., 2006) . NPM is involved in centrosome duplication and spindle pole formation although further investigations are required to establish if NPM is a critical target of BRCA1/BARD1 during mitosis.
It was reported that ARF mediates NPM polyubiquitination and degradation upon ectopic overexpression in cells (Itahana et al., 2003) , although these data have not been confirmed (Brady et al., 2004) . More recently, it has been shown that NPM is de-ubiquitinated by the nucleolar pool of the ubiquitin specific peptidase 36 (USP36) favoring NPM stabilization (Endo et al., 2009b) and, on the other hand, NPM is required for the nucleolar accumulation of USP36 (Endo et al., 2009a) . Therefore, in the absence of NPM, there is an increased poly-ubiquitination of nucleolar fibrillarin (another USP36 target) thus suggesting that NPM, through USP36, might control the level of protein ubiquitination in the nucleolus.
Poly-(ADP-ribosyl)ation NPM binds to Poly-(ADP-ribose) polymerases 1 and 2 (PARP1 and 2) (Meder et al., 2005) and is poly-(ADPribosyl)ated following ionizing radiation (Ramsamooj et al., 1995) , although it is not clear if PARP1 and/or 2 catalyze the reaction. Although PARP1 has been involved in a number of cellular functions overlapping with reported NPM activities such as DNA repair and replication, chromatin modulation, insulation, transcription, apoptosis and differentiation (Kraus, 2008) , it is not known at the moment if and how NPM and PARP1/2 may influence each other's activities.
NPM is required in vivo for DNA integrity and chromosome stability NPM has been widely implicated both in the maintenance of DNA integrity, either preventing or repairing DNA damage, and in the regulation of chromosomal stability through the control of centrosome duplication and mitosis. However, little is known about the molecular mechanisms underlying these functions of NPM and moreover, it is not clear if in vivo absence of NPM has any impact on DNA integrity or chromosome number. Interesting insights emerge from the study of NPM knock out models.
NPM protects DNA integrity not only following external stimuli (Li et al., , 2007 but also in steadystate conditions. NpmÀ/À mouse embryos die in uterus at 10.5 dpc, display widespread apoptosis, p53 upregulation and accumulation of g-H2AX foci (a marker of damaged DNA and DDR) (Colombo et al., 2005) . These observations were also confirmed in NpmÀ/À murine hematopoietic precursors derived from the yolk sac, where reintroduction of NPM was sufficient to revert this phenotype (Colombo et al., 2005) . Available data do not allow to discriminate if the accumulation of g-H2AX foci is due to a direct involvement of NPM in the DNA repair machinery (Borggrefe et al., 1998; Koike et al., 2010) , or if it is the indirect consequence of other NPM activities such as chromatin organization (Frehlick et al., 2007) and/or DNA replication (Takemura et al., 1999; Okuwaki et al., 2001a) . Increased proliferation imposed by non-physiological growth promoting signals or oncogene expression leads to replication stress and accumulation of damaged DNA (Bartkova et al., 2006; Di Micco et al., 2006) . Interestingly, NpmÀ/À embryos show an increased proliferative rate (measured as increased number of cells that incorporate Bromodeoxyuridine) (Colombo et al., 2005) .
On the other hand, Grisendi et al. (2005) have shown the presence of multiple centrosomes and abnormal mitosis in both NpmÀ/À embryonic tissue and in embryo derived cells, confirming a still molecular undefined role for NPM in controlling centrosome duplication and/or mitotic spindle formation. Indeed, the observed alterations are also compatible with a specific role of NPM in either (or both) of the two pathways.
NPM and cancer
Many reports correlate NPM to cancer pathogenesis. This may not be surprising, as many of the activities ascribed to NPM can be related to what is currently known about tumor development. However, the specific contribution of NPM is far from being clearly defined, as most of the conclusions drawn so far are still prevalently based on indirect evidence using in vitro models, whereas in vivo data on suitable mouse models of carcinogenesis are still missing. In particular, an open issue in the field remains: is NPM a proto-oncogene or a tumor suppressor gene? As it will become clear, NPM behaves both ways and, at the moment, it is still difficult to reconcile all the available data.
NPM overexpression has been reported in carcinomas of different origin: ovarian, prostate, colon and bladder (Yung, 2007) and often correlates with mitotic index and proliferation rate. In bladder cancer, NPM overexpression is a prognostic marker for recurrence and progression (Yung, 2007) . The correlation between increased NPM levels and cancer has been mainly linked to the role of NPM in ribosome biogenesis and protein synthesis, functions that are both increased in cancer cells (Roussel and Hernandez-Verdun, 1994) . Amplification of the NPM1 locus has never been reported in cancer specimens; however, as NPM1 is a c-Myc target gene its overexpression may be the result of increased c-Myc activity. Moreover, there are no studies that investigate if NPM is mutated in these tumors, or if there are alterations in the post-translational modifications of the protein that may influence its activity, localization and stability. No transgenic models of NPM overexpression are available to date that could provide in vivo evidence that NPM overexpression is per se enough to trigger the tumorigenic process.
NPM overexpression in immortalized cell lines leads to increased proliferation and transformation (Yung, 2007) , and NPM cooperates with oncogenes in inducing cellular transformation in MEFs (Li et al., 2007 (Li et al., , 2008 . Interestingly, overexpressed NPM strongly reduces the level of DNA damage (measured as g-H2AX accumulation) imposed by oncogenes, and it reduces the oncogene-dependent apoptotic or senescence response. This result is even more evident in MEFs defective in DNA repair proteins such as ATM and FANCC (Li et al., 2007) .
On the other hand, Grisendi et al., (2005) have shown that Em-myc mice in an Npm þ /À background, which expresses lower NPM levels, show a significant acceleration in lymphoma onset. Moreover, Npm þ /À animals may develop hematological neoplasms late in life (with higher incidence of myeloid malignancies) significantly more frequently that their Npm þ / þ counterparts, suggesting that NPM is a haploinsufficient tumor suppressor for the hematopoietic compartment (Sportoletti et al., 2008) . They also showed that Npm þ /À MEFs display a slower growth rate compared with wildtype MEFs between passages 2 and 6, after which they overcome senescence, become immortalized and grow faster than WT controls, show increased genomic instability and, when infected with oncogene expressing viruses, are transformed at higher frequency. Consistently, Npm þ /À MEFs overexpressing oncogenes at lower passage, show decreased cellular transformation in vitro compared with Npm þ / þ MEFs.
All these data suggest a model in which NPM can contribute to tumor development in different ways, depending on the time when NPM haploinsufficiency or oncogene activation arises in the cell (Figure 2) . If oncogene activation arises as the first genetic event in a normal cell, the consequent accumulation of DNA damage should increase the chance to select mutations leading to DDR escape, before DDR itself induces cell death or senescence (Bartkova et al., 2006; Di Micco et al., 2006) (Figure 2a) . NPM may favor this process by keeping the level of damage and DDR response below a threshold that cells can tolerate, therefore enabling the selection of the necessary cooperating mutation. In light Nucleophosmin and its complex network E Colombo et al of this, it is not surprising that NPM overexpression is more powerful in MEFs defective for DNA repair proteins. On the other hand, if NPM haploinsufficiency arises first, cells will slowly accumulate genomic instability, and thus the surviving cells would have already selected for mutations that escape the DDR pathway. The activated oncogene would not find any barrier to transformation in these cells, and they could be immediately transformed rendering NPM overexpression dispensable (Figure 2b) .
Loss of the second Npm1 allele is never selected in Npm þ /À animals that develop hematological tumors, suggesting that either loss of the second allele is not required for transformation or that tumor cells cannot tolerate the complete loss of NPM expression. The latter may be related to NPM activities required for cancer cells to proliferate and survive, such as, for example, mitosis and ribosome biogenesis or anti-apoptotic and pro-survival functions. This may explain why depletion of NPM or use of a truncated dominant negative NPM protein can sensitize cancer cells to apoptosis (Li et al., 2005; Zhou et al., 2008) . Although these results open the fascinating possibility of using NPM as a target to induce cancer cell death (Jian et al., 2009) , it must be considered that a partial targeting of NPM in normal tissues may trigger or favor the initial stages of tumor development.
Role of NPM in human hematological malignancies
The NPM1 gene is frequently involved in chromosomal translocations or mutations, invariably restricted to the hematopoietic compartment and associated to the development of leukemias or lymphomas (Falini et al., 2007) . Three chromosomal translocations involving NPM1 have been identified so far. The t(2;5) translocation, found in B30% of anaplastic large cell lymphomas (Morris et al., 1994) , fuses the 5 0 end of the NPM1 gene on chromosome 5 (encoding for the first 117aa of the NPM protein) to the 3 0 portion of the ALK locus on chromosome 2, encoding the catalytic domain of ALK, a receptor tyrosine kinase normally expressed only in the nervous system. The result is the abnormal expression in the lymphoid compartment of a fusion protein (NPM-ALK) in which the NPM homo-dimerization interface leads to constitutive activation of the ALK kinase. NPM-ALK can associate with many different adaptor proteins normally involved in transducing tyrosine kinase receptor signals, such as SHC, Grb2 and IRS-1, thereby activating intracellular pathways such as RAS-MAPK, JAK-STAT, PI3K-Akt and PLCg, that in turn promote cell proliferation and provide anti-apoptotic signals (Amin and Lai, 2007) . Therefore, constitutive ALK activation is a key feature for the oncogenic activity of the NPM-ALK fusion protein. Accordingly, NPM-ALK transgenic mice develop T-cell tumors resembling human anaplastic large cell lymphomas (Chiarle et al., 2003) .
The t(5;17)(q35;q21) translocation is a rare variant, isolated so far in only four cases of human acute promyelocytic leukemia (Redner et al., 1996) . In the resulting fusion protein, the N-terminal portion of NPM (first 117aa) is fused to the C-terminal portion of the retinoic receptor alpha (RARa), including its DNA binding domain. Also in this case, NPM provides the homo-dimerization interface required for RARa activity and, similarly to the most frequent fusion protein found in acute promyelocytic leukemia, PML-RARa, the NPM-RARa chimera recruits co-repressor proteins that interfere with RARa-dependent transcriptional activities (Redner et al., 2000) . The consequence is a block of the myeloid differentiation program that can be released by treatment with pharmacological doses of all-trans retinoic acid (Okazuka et al., 2007) .
The t(3;5)(q25;q35) is the third translocation involving the NPM1 gene and has been isolated in o1% of acute myeloid leukemia (AML) (Yoneda-Kato et al., 1996) . The resulting fusion protein contains a larger portion of the N terminus of NPM (first 175aa) fused to virtually the entire coding sequence of a previously unknown protein, MLF1 (myelodysplasia/myeloid leukemia factor 1). Little is known about the biological activity of the NPM-MLF1 fusion protein, but it is capable of transforming MEFs in cooperation with the oncogenic mutant RASV12 (Yoneda-Kato and Kato, 2008). The wild-type MLF1 protein is involved in p53 stabilization (Yoneda-Kato et al., 2005) , an activity that correlates to its nuclear localization. Interestingly, in the presence of NPM-MLF1, the WT MLF1 protein is partially retained in the nucleolus. It is worth noting that a proportion of AML/myelodysplastic syndromes (MDS) cases bearing the t(3;5) rearrangement show breakpoints located outside the NPM1 and MLF1 genes, with a deletion in chromosome 5 that includes the NPM1 locus, similarly to that observed in myelodysplastic syndromes with 5q deletion (Berger et al., 2006) . These data support the concept that NPM haploinsufficiency per se may cause myeloproliferative neoplasms, as observed in Npm þ /À mice (Grisendi et al., 2005) .
The contribution of the NPM portion to the oncogenic activity of these fusion proteins is still under investigation. At least in the case of NPM-RARa and NPM-ALK, the fact that the same tumor type is also associated to other translocations in which the NPM portion is substituted by other genes, indicates that the ALK and RARa moieties are indispensable for tumor formation whereas NPM may serve to provide a homo-dimerization interface plus a strong promoter to drive high levels of expression of the chimera in the hematopoietic compartment. However, it must be considered that these translocations also lead to a situation of haploinsufficiency for the WT NPM1 gene and, moreover, all three fusion proteins bind to the WT NPM protein altering its cellular localization (Naoe et al., 2006) . Interestingly, in vivo experiments of mice bone marrow transplantation with hematopoietic progenitor cells infected either with viruses expressing NPM-ALK or the variant H4-ALK (in which the NPM portion has been substituted with an inert dimerization interface), showed that both constructs led to lymphoma onset with the same frequency (unpublished observations). However, in the case of NPM-ALK, the latency was significantly reduced, thus suggesting that NPM may contribute to reducing the interval required for the second cooperating hit to be selected, and strengthening the putative role of NPM in controlling genome integrity.
Perhaps the most suggestive indication that NPM activity is involved in tumor pathogenesis comes from the discovery that B35% of AML cases bear a mutation in one of the two NPM1 alleles (Falini et al., 2005) . A constant immunohistochemical hallmark of AML with mutated NPM1 is the cytoplasmic NPM staining in bone marrow-derived tumor specimens, leading to the general definition of NPMc þ (cytoplasmic positive) AML (Falini et al., 2006b) . With very few exceptions (Mariano et al., 2006; Albiero et al., 2007) , virtually all the NPM1 mutations thus far described occur in the last exon of the NPM1 gene, and lead to the de novo formation of a new nuclear export signal in the Cterminal part of the NPM mutated protein (Figure 1) , which alters the normal balance in nuclear-cytoplasmic NPM shuttling and causes the characteristic cytoplasmic localization (Mariano et al., 2006; Falini et al., 2006a; Bolli et al., 2007) .
NPM1 gene mutations represent the most frequent genetic alterations found in adult AML, whereas they are much less represented in childhood AML (Cazzaniga et al., 2005; Brown et al., 2007) . NPMc þ AML have been found in all morphological FAB subtypes, except for acute promyelocytic leukemia, and increasing evidence suggests that they may represent a distinct AML subtype with common pathological, immunophenotypic and prognostic features. NPMc þ AMLs are frequently CD34 negative (Taussig et al., 2010) and they often show multi-lineage involvement (Pasqualucci et al., 2006) . However, it has been recently shown that the rare CD34 þ blasts purified from these patients can engraft in immunocompromised mice and support the development of a leukemia that recapitulates the original patient's disease (Martelli et al., 2010) . NPM1 mutations arise, in most cases, in primary AML, they are not present in other tumor types (Falini et al., 2005) , and they have rarely been found in myeloproliferative or myelodysplastic disorders (Caudill et al., 2006; Oki et al., 2006; Zhang et al., 2007) or in secondary AML. In the latter cases, it cannot be excluded that they indicate a de novo AML following chemotherapy (Andersen et al., 2008; Falini, 2008) . NPM1 mutations are always mutually exclusive with other known recurrent genomic abnormalities associated to AML pathogenesis, such as t(15;17), t(8;21), t(6;9), inv(16) , and they are significantly associated with a normal karyotype (about 85% of NPMc þ AML). NPM1 mutations are often the only genetic abnormality detected in AML blasts and are very stable during the course of the disease (Meloni et al., 2008) , therefore likely representing a reliable marker for monitoring minimal residual disease . Only 15% of NPMc þ AML show a complex karyotype, although in these cases chromosomal alterations are often present only in a portion of AML blasts, suggesting they represent secondary events (Haferlach et al., 2009) . Accordingly, no differences have been found in terms of clinical or biological behavior between NPMc þ AML with normal karyotype or those bearing additional chromosomal abnormalities Haferlach et al., 2009) .
On the other hand, a significant correlation has been reported between NPM mutations and another frequent genetic abnormality found in AML: FLT3-ITD (internal tandem duplication of the fms-related tyrosine kinase 3 gene) (Falini et al., 2005) . NPM1 mutations likely precede the appearance of FLT3-ITD, further suggesting they represent a primary genetic event. Interestingly, NPMc þ AML that are FLT3-ITD negative have a better prognosis due to higher remission rate after chemotherapy (Dohner et al., 2005; Schnittger et al., 2005; Suzuki et al., 2005; Thiede et al., 2006; Mrozek et al., 2007; Schlenk et al., 2008) . The molecular basis of this increase in response to therapy is not completely elucidated. One possible explanation may involve nuclear factor-kB, which is frequently upregulated in AML blasts (Guzman et al., 2001) and is involved in inducing pharmacological resistance (Frelin et al., 2005) by inhibiting apoptosis and promoting cell survival. The mutant NPM delocalizes and inactivates nuclear factorkB, therefore increasing chemosensitivity (Cilloni et al., 2008) . Recently, Del Poeta et al. (2010) have shown that NPMc þ FLT3-ITD negative AMLs have a higher transcript ratio between the anti-apoptotic BAX and the pro-apoptotic BCL2 mRNAs, which may sensitize AML blasts to apoptosis.
A further indication that NPMc þ AML may represent a new clinical entity comes from gene expression profile studies. AML with mutated NPM1 show a specific gene expression signature characterized by increased expression of homeo-box genes and other genes involved in stem cell maintenance Verhaak et al., 2005; Wilson et al., 2006) . Accordingly, a specific miRNA profile linked to the regulation of the HOX gene expression is also associated to NPMc þ leukemia (Garzon et al., 2008; JongenLavrencic et al., 2008) .
All the available data on NPMc þ AML point at a crucial role of the NPM mutated protein in disease development. Although a formal proof that mutant NPM possesses oncogenic potential in vivo is still missing, a number of observations in vitro strongly support this hypothesis. NPMc þ causes the abnormal cytoplasmic localization of several NPM interactors, leading to their inactivation and in some cases favoring their degradation (den Besten et al., 2005; Colombo et al., 2006; Bonetti et al., 2008; Cilloni et al., 2008; Gurumurthy et al., 2008; Wanzel et al., 2008) . In particular, NPMc þ inactivates relevant tumor suppressor proteins including Miz1, ARF and Fbw7g. Fbw7g is an E3 ubiquitin ligase involved in c-Myc degradation, therefore its inactivation leads to the overexpression of c-Myc in cells expressing NPMc þ . Miz1 is a transcription factor that activates the expression of two important cell cycle inhibitors, p15Ink4b and p21.
NPMc þ delocalizes Miz1 to the cytoplasm, favoring uncontrolled cell cycle progression. Finally, ARF in the presence of NPMc þ is delocalized to the cytoplasm too and degraded, thus blocking the ARF-dependent p53 stabilization that would be induced by c-Myc overexpression (Zindy et al., 1998) . Based on these data, NPMc þ is an oncoprotein that can simultaneously lead to oncogene overexpression (c-Myc) and deactivate physiological cellular barriers (ARF, p21, p15Ink4b) that would limit uncontrolled proliferation (Schmitt et al., 1999) , two key events in tumor development. Interestingly, NPMc þ overexpression in MEFs, either WT, p53À/À or ARFÀ/À, is not sufficient to induce transformation in vitro. Moreover, NPMc þ does not cooperate with RasV12 in inducing transformation, whereas it does cooperate with E1A, which exerts its transforming activity by inactivating the pRb oncosuppressor protein, thus suggesting that NPMc þ may indirectly activate the Rb pathway (Cheng et al., 2007) .
As only one allele of NPM is mutated, all NPMc þ AML are characterized by haploinsufficient expression of the WT NPM protein; in addition, NPMc þ interacts with WT NPM through their homo-dimerization interfaces and it can alter its localization (Falini et al., 2006a; Bolli et al., 2007) . The extent of cytoplasmic delocalization of WT NPM in in vitro experiments depends on the expression levels of NPMc þ , whereas the situation in vivo is less clear. In fact, using an antibody that recognizes both WT and mutated NPM in AML bone marrow specimens, Bolli et al., (2009) found a high level of heterogeneity among samples. Gruszka et al. (2010) , using antibodies that specifically recognize either the mutant or the WT NPM protein showed that, in NPMc þ AML blasts, a sizable fraction of mutant and WT NPM proteins remains in separate cellular compartments (cytoplasmic and nuclear/nucleolar, respectively). However, it remains unclear whether partial delocalization of the WT NPM protein has a crucial role in the pathogenic activity of the NPMc þ protein. In particular, we cannot exclude that NPMc þ not only acts as a dominant-negative protein over WT NPM, but has also acquired new functions and/or has 'superphysiological' activities that correlate to its increased nuclear export capacity. For example, NPMc þ may affect export of pre-ribosomal particles, regulation of centrosomal duplication or other molecularly undefined mitotic activities. In this respect, it is worth noting that NPMc þ AML has, in most cases, a normal karyotype, thus indicating that the activity of NPM in preserving chromosomal stability is maintained in these tumors.
Concluding remarks and future perspectives
Besides the ongoing efforts to define the molecular basis of the pathogenic activity of NPMc þ , at the clinical level it already represents an important prognostic and predictive marker in AML. The presence of NPM1 mutations (with a wild type FLT3 gene) is a favorable marker for relapse free survival and over-all survival in normal karyotype AML and for complete remission after intensive induction therapy.
Interestingly, the retrospective analysis of a cohort of elderly AML patients treated with all-trans retinoic acid together with conventional chemotherapy showed a beneficial effect in patients with mutant NPM (Schlenk et al., 2009) . These data were, however, not confirmed when studying younger patients (Burnett et al., 2009) . The molecular basis of this response remains elusive, but it may correlate with the reported role of NPM as co-repressor of AP2a during retinoic acid-induced differentiation, including the NPM1 promoter itself (Liu et al., 2007a) .
These findings further support the idea that mutant NPM may represent a good therapeutic target. The main problem with this approach is its specificity, considering that the mutant is very similar to the wildtype protein. The mutated C-terminal region seems to be unfolded compared with the wild type (Grummitt et al., 2008) , although it is not yet clear if this region may influence the overall structure of NPM and, in particular, the interaction between NPM mutant and other proteins like ARF. It will be important in the future to define the 3D structure of wild type versus mutant NPM bound to ARF in order to understand if it is possible to design small molecules that specifically block the interaction between NPM mutant and ARF. Alternatively, it may be easier to treat patients with compounds like nutlins that mimic ARF activity inhibiting the HDM2-p53 interaction (Vassilev et al., 2004) . Indeed, lack of ARF activity in NPMc þ AML correlates with the finding that p53 is rarely mutated (Suzuki et al., 2005) suggesting that there is no genetic pressure on the ARF-HDM2-p53 pathway. Accordingly, it should be possible to activate p53 in blasts using DNA damaging drugs and this may explain why NPMc þ leukemia are generally very sensitive to chemotherapy.
Another possible approach is to target the abnormal nuclear export of NPMc þ . It has been shown in vitro that it is possible to relocate NPMc þ and ARF in the nucleus (but not in the nucleolus) using inhibitors of proteins involved in nuclear export such as exportin-1 (CRM1) like leptomycin B (Fukuda et al., 1997) , and that this relocation is enough to stabilize ARF . However, it is difficult to understand the long-term effect of this relocation, as leptomycin B is per se toxic and, indeed, cannot be used for in vivo treatment (Kau and Silver, 2003) . Interestingly, alternative less toxic semi-synthetic leptomycin B derivatives have been selected (Mutka et al., 2009) . High-throughput, small molecule screens using mislocalized proteins as read-out have proved to be a powerful tool for the selection of chemicals that inhibit yet unknown pathways involved in the trafficking of defined delocalized molecules; these compounds have more chances to be specific, and hopefully less toxic .
Last, but not least, a mouse model of NPMc þ -dependent AML still needs to be created. Cheng and et al. have recently reported the generation of a transgenic mouse expressing the NPMc þ complementary DNA under the control of the myeloid-specific human MRP8 promoter. These mice show increased myeloproliferation in bone marrow and spleen progressively in life, but they do not develop overt AML (Cheng et al., 2009) . However, these data demonstrated for the first time that mutant NPM can increase the proliferative potential of myeloid cells. This aspect was confirmed also in the zebrafish model system, in which expression of NPMc þ causes an embryonic expansion of primitive myeloid and definitive hematopoietic cells (Bolli et al., 2010) . Although these models provide evidence concerning the capability of NPMc þ to perturb normal hematopoiesis, they still do not provide a definitive NPMc þ dependent AML model system. This failure may be ascribed to problems in reaching the correct expression levels, as NPMc þ has to compete with WT NPM, and/or to the lack of cooperative mutations, like FLT3-ITD or, as shown more recently, DNMT3A (Ley et al., 2010) . Therefore, more efforts need to be engaged in this direction, not only because this model will definitely prove the tumorigenic activity of NPMc þ but, more importantly, because it will provide a valuable tool to verify the in vivo efficacy of new therapeutic approaches.
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